Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Absci CorpABSI · Entity 4685 | Director | July 26, 2021 | July 28, 2021 |
| GeneDx Holdings Corp.WGS · Entity 1634 | Director · 10% owner | June 04, 2026 | June 08, 2026 |
| STANDARD BIOTOOLS INC.LAB · Entity 6116 | Director · 10% owner | December 02, 2025 | December 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Absci Corp
Report date July 26, 2021 · Filed July 28, 2021
Jointly reported with Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC, Casdin Private Growth Equity Fund, L.P., CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,745,333 |
Last balance in matching sequence
After 2021-07-26 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2021-07-26 · Conversion · Acquired 4,209,573 · Balance 4,209,573 F1: These shares of the Series E Preferred Stock automatically converted on a one-for-3.3031 basis into the number of shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), shown in Column 7 immediately upon closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series E Preferred Stock had no expiration date. F2: These shares are held by Casdin Partners Master Fund, L.P. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Partners Master Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Partners GP. Each of Casdin Capital, Casdin Partners GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports Row 2 · 2021-07-26 · Conversion · Acquired 973,260 · Balance 5,182,833 F3: This convertible promissory note ("Convertible Note") had a maturity date of September 16, 2023. The principal and accrued interest under the Convertible Note converted upon the closing of the IPO into shares of Common Stock at a conversion price equal to $13.12 per share without payment of additional consideration. F2: These shares are held by Casdin Partners Master Fund, L.P. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Partners Master Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Partners GP. Each of Casdin Capital, Casdin Partners GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports Row 3 · 2021-07-26 · Purchase · Acquired 1,562,500 · Balance 6,745,333 F2: These shares are held by Casdin Partners Master Fund, L.P. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Partners Master Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Partners GP. Each of Casdin Capital, Casdin Partners GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 973,260 |
Reported balance
After 2021-07-26 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2021-07-26 · Conversion · Acquired 973,260 · Balance 973,260 F3: This convertible promissory note ("Convertible Note") had a maturity date of September 16, 2023. The principal and accrued interest under the Convertible Note converted upon the closing of the IPO into shares of Common Stock at a conversion price equal to $13.12 per share without payment of additional consideration. F4: These shares are held by Casdin Private Growth Equity Fund, L.P. Casdin Capital is the investment adviser to Casdin Private Growth Equity Fund, L.P. and Casdin Private Growth Equity Fund GP, LLC ("Casdin Private Growth GP") is the general partner of Casdin Private Growth Equity Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Private Growth GP. Each of Casdin Capital, Casdin Private Growth GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports. |
| Series E Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-07-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-07-26 · Conversion · Disposed 1,274,431 · Balance 0 F1: These shares of the Series E Preferred Stock automatically converted on a one-for-3.3031 basis into the number of shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), shown in Column 7 immediately upon closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series E Preferred Stock had no expiration date. F2: These shares are held by Casdin Partners Master Fund, L.P. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Partners Master Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Partners GP. Each of Casdin Capital, Casdin Partners GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports |
| Convertible NoteSEC Table II · derivative / convertible security · Conversion / exercise price $13.12 | Direct | 0 |
Reported balance
After 2021-07-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-07-26 · Conversion · Disposed Not disclosed · Balance 0 F3: This convertible promissory note ("Convertible Note") had a maturity date of September 16, 2023. The principal and accrued interest under the Convertible Note converted upon the closing of the IPO into shares of Common Stock at a conversion price equal to $13.12 per share without payment of additional consideration. F2: These shares are held by Casdin Partners Master Fund, L.P. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Partners Master Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Partners GP. Each of Casdin Capital, Casdin Partners GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports |
| Convertible NoteSEC Table II · derivative / convertible security · Conversion / exercise price $13.12 | IndirectSee footnote | 0 |
Reported balance
After 2021-07-26 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-07-26 · Conversion · Disposed Not disclosed · Balance 0 F3: This convertible promissory note ("Convertible Note") had a maturity date of September 16, 2023. The principal and accrued interest under the Convertible Note converted upon the closing of the IPO into shares of Common Stock at a conversion price equal to $13.12 per share without payment of additional consideration. F4: These shares are held by Casdin Private Growth Equity Fund, L.P. Casdin Capital is the investment adviser to Casdin Private Growth Equity Fund, L.P. and Casdin Private Growth Equity Fund GP, LLC ("Casdin Private Growth GP") is the general partner of Casdin Private Growth Equity Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Private Growth GP. Each of Casdin Capital, Casdin Private Growth GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of the Series E Preferred Stock automatically converted on a one-for-3.3031 basis into the number of shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), shown in Column 7 immediately upon closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series E Preferred Stock had no expiration date.
F2: These shares are held by Casdin Partners Master Fund, L.P. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Partners Master Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Partners GP. Each of Casdin Capital, Casdin Partners GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports
F3: This convertible promissory note ("Convertible Note") had a maturity date of September 16, 2023. The principal and accrued interest under the Convertible Note converted upon the closing of the IPO into shares of Common Stock at a conversion price equal to $13.12 per share without payment of additional consideration.
F4: These shares are held by Casdin Private Growth Equity Fund, L.P. Casdin Capital is the investment adviser to Casdin Private Growth Equity Fund, L.P. and Casdin Private Growth Equity Fund GP, LLC ("Casdin Private Growth GP") is the general partner of Casdin Private Growth Equity Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Private Growth GP. Each of Casdin Capital, Casdin Private Growth GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports.
GeneDx Holdings Corp.
Report date June 04, 2026 · Filed June 08, 2026
Jointly reported with Casdin Eli, Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectSee footnote | 3,657,164 |
Reported balance
After 2026-06-04 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-06-04 · Purchase · Acquired 150,000 · Balance 3,657,164 F1: The securities are owned directly by the Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. |
| Class A Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectSee footnote | 3,707,164 |
Reported balance
After 2026-06-05 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2026-06-05 · Purchase · Acquired 50,000 · Balance 3,707,164 F1: The securities are owned directly by the Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. |
| Class A Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectSee footnote | 19,247 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 19,247 F3: The securities are owned directly by the GP and may be deemed to be indirectly beneficially owned by Eli Casdin, the managing member of the GP. |
| Class A Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectSee footnote | 333,144 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 333,144 F4: The securities are owned directly by CMLS Holdings LLC ("CMLS Holdings"). The Board of Managers of CMLS Holdings includes Eli Casdin, who, as a member of the Board of Managers of CMLS Holdings, shares voting and investment discretion with respect to the common stock held by CMLS Holdings. |
| Class A Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 20,517 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 20,517 F2: The securities are owned directly by Eli Casdin. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities are owned directly by the Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.
F2: The securities are owned directly by Eli Casdin.
F3: The securities are owned directly by the GP and may be deemed to be indirectly beneficially owned by Eli Casdin, the managing member of the GP.
F4: The securities are owned directly by CMLS Holdings LLC ("CMLS Holdings"). The Board of Managers of CMLS Holdings includes Eli Casdin, who, as a member of the Board of Managers of CMLS Holdings, shares voting and investment discretion with respect to the common stock held by CMLS Holdings.
STANDARD BIOTOOLS INC.
Report date December 02, 2025 · Filed December 05, 2025
Jointly reported with Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC, Casdin Private Growth Equity Fund II, L.P., CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC, Casdin Private Growth Equity Fund II GP, LLC, Casdin Private Growth Equity Fund, L.P., Casdin Eli
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | IndirectSee footnote | 71,875,000 |
Reported balance
After 2025-12-02 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2025-12-02 · Purchase · Acquired 125,000 · Balance 71,875,000 F1: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4050 to $1.4351. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. |
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | IndirectSee footnote | 71,950,000 |
Reported balance
After 2025-12-03 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2025-12-03 · Purchase · Acquired 75,000 · Balance 71,950,000 F2: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4403 to $1.4406. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. |
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | IndirectSee footnote | 72,100,000 |
Reported balance
After 2025-12-04 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2025-12-04 · Purchase · Acquired 150,000 · Balance 72,100,000 F3: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4331 to $1.4588. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. |
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | IndirectSee footnote | 13,939,637 |
Reported balance
Holding disclosure · report date 2025-12-02 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 13,939,637 F6: The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin. |
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | IndirectSee footnote | 2,744,219 |
Reported balance
Holding disclosure · report date 2025-12-02 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 2,744,219 F7: The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin. |
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | Direct | 2,901,062 |
Reported balance
Holding disclosure · report date 2025-12-02 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 2,901,062 F5: The securities are owned directly by Eli Casdin. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4050 to $1.4351. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4403 to $1.4406. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4331 to $1.4588. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
F4: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP.
F5: The securities are owned directly by Eli Casdin.
F6: The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.
F7: The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.
Past disclosures · reporting ended (7)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
2seventy bio, Inc.
Report date May 13, 2025 · Filed May 15, 2025
Jointly reported with Casdin Eli, Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC
Section 16 reporting ended · disclosed 2025-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-05-13 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-05-13 · Other · Disposed 22,625 · Balance 0 F1: Represents securities that were tendered in connection with the Agreement and Plan of Merger (the "Merger Agreement"), dated March 10, 2025, by and among 2seventy bio, Inc. (the "Company"), Daybreak Merger Sub Inc. ("Merger Sub") and Bristol-Myers Squibb Company ("Parent"). Following completion of a cash tender offer by Merger Sub to acquire all of the issued and outstanding shares of the Company's common stock, par value $0.0001 per share (the "Company Common Stock") for $5.00 per share (the "Merger Consideration"), Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a whole owned subsidiary of Parent (the "Merger"). F2: cont'd from footnote (1): Each restricted stock unit in respect of Company Common Stock ("Company RSU Award"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Additionally, effective as of the Effective Time and as a result of the Merger, Eli Casdin ceased to be a member of the Company's board of directors. F3: The securities were owned directly by Eli Casdin. |
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2025-05-13 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2025-05-13 · Other · Disposed 2,000,000 · Balance 0 F1: Represents securities that were tendered in connection with the Agreement and Plan of Merger (the "Merger Agreement"), dated March 10, 2025, by and among 2seventy bio, Inc. (the "Company"), Daybreak Merger Sub Inc. ("Merger Sub") and Bristol-Myers Squibb Company ("Parent"). Following completion of a cash tender offer by Merger Sub to acquire all of the issued and outstanding shares of the Company's common stock, par value $0.0001 per share (the "Company Common Stock") for $5.00 per share (the "Merger Consideration"), Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a whole owned subsidiary of Parent (the "Merger"). F2: cont'd from footnote (1): Each restricted stock unit in respect of Company Common Stock ("Company RSU Award"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Additionally, effective as of the Effective Time and as a result of the Merger, Eli Casdin ceased to be a member of the Company's board of directors. F4: The securities were owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to have been indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.93 | Direct | 0 |
Reported balance
After 2025-05-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-13 · Disposition to issuer · Disposed 12,050 · Balance 0 F5: Each option to purchase Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company Option immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. F3: The securities were owned directly by Eli Casdin. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.54 | Direct | 0 |
Reported balance
After 2025-05-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-05-13 · Disposition to issuer · Disposed 33,400 · Balance 0 F5: Each option to purchase Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company Option immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. F3: The securities were owned directly by Eli Casdin. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents securities that were tendered in connection with the Agreement and Plan of Merger (the "Merger Agreement"), dated March 10, 2025, by and among 2seventy bio, Inc. (the "Company"), Daybreak Merger Sub Inc. ("Merger Sub") and Bristol-Myers Squibb Company ("Parent"). Following completion of a cash tender offer by Merger Sub to acquire all of the issued and outstanding shares of the Company's common stock, par value $0.0001 per share (the "Company Common Stock") for $5.00 per share (the "Merger Consideration"), Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a whole owned subsidiary of Parent (the "Merger").
F2: cont'd from footnote (1): Each restricted stock unit in respect of Company Common Stock ("Company RSU Award"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Additionally, effective as of the Effective Time and as a result of the Merger, Eli Casdin ceased to be a member of the Company's board of directors.
F3: The securities were owned directly by Eli Casdin.
F4: The securities were owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to have been indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.
F5: Each option to purchase Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company Option immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option.
BIOLIFE SOLUTIONS INC
Report date May 19, 2026 · Filed May 21, 2026
Jointly reported with Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC, Casdin Eli
Section 16 reporting ended · disclosed 2026-05-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectSee footnote | 4,757,165 |
Last balance in matching sequence
After 2026-05-21 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2026-05-19 · Sale · Disposed 300,000 · Balance 5,657,165 F1: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin Capital"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Row 2 · 2026-05-20 · Sale · Disposed 250,000 · Balance 5,407,165 F1: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin Capital"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Row 3 · 2026-05-21 · Sale · Disposed 650,000 · Balance 4,757,165 F1: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin Capital"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin Capital"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP.
CONSTELLATION PHARMACEUTICALS INC
Report date July 23, 2018 · Filed July 23, 2018
Jointly reported with Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC, Casdin Eli, Casdin Venture Opportunities Fund, L.P., CASDIN VENTURE OPPORTUNITIES FUND GP, LLC
Section 16 reporting ended · disclosed 2018-07-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 345,783 |
Reported balance
After 2018-07-23 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-07-23 · Conversion · Acquired 345,783 · Balance 345,783 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2: These securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 612,450 |
Reported balance
After 2018-07-23 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-07-23 · Purchase · Acquired 266,667 · Balance 612,450 F2: These securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 158,960 |
Reported balance
After 2018-07-23 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2018-07-23 · Conversion · Acquired 158,960 · Balance 158,960 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F3: These securities are owned directly by Casdin Venture Opportunities Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Venture Opportunities Fund, LP, (ii) Casdin Venture Opportunities Fund GP, LLC, the general partner of Casdin Venture Opportunities Fund, LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Venture Opportunities Fund GP, LLC. |
| Series E Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2018-07-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-07-23 · Conversion · Disposed 1,333,333 · Balance 0 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2: These securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. |
| Series E-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2018-07-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-07-23 · Conversion · Disposed 342,435 · Balance 0 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2: These securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. |
| Series F Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2018-07-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-07-23 · Conversion · Disposed 1,750,000 · Balance 0 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2: These securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. |
| Series F Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2018-07-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-07-23 · Conversion · Disposed 1,750,000 · Balance 0 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F3: These securities are owned directly by Casdin Venture Opportunities Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Venture Opportunities Fund, LP, (ii) Casdin Venture Opportunities Fund GP, LLC, the general partner of Casdin Venture Opportunities Fund, LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Venture Opportunities Fund GP, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.
F2: These securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
F3: These securities are owned directly by Casdin Venture Opportunities Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Venture Opportunities Fund, LP, (ii) Casdin Venture Opportunities Fund GP, LLC, the general partner of Casdin Venture Opportunities Fund, LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Venture Opportunities Fund GP, LLC.
Fulcrum Therapeutics, Inc.
Report date July 22, 2019 · Filed July 22, 2019
Jointly reported with Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC, Casdin Eli
Section 16 reporting ended · disclosed 2019-07-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 604,285 |
Last balance in matching sequence
After 2019-07-22 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2019-07-22 · Conversion · Acquired 464,285 · Balance 464,285 F1: On July 22, 2019, the Series B Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: The securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Row 2 · 2019-07-22 · Purchase · Acquired 125,000 · Balance 589,285 F2: The securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Row 3 · 2019-07-22 · Purchase · Acquired 10,000 · Balance 599,285 F2: The securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Row 4 · 2019-07-22 · Purchase · Acquired 5,000 · Balance 604,285 F2: The securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2019-07-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-07-22 · Conversion · Disposed 3,250,000 · Balance 0 F1: On July 22, 2019, the Series B Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: The securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 22, 2019, the Series B Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
F2: The securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
Section 16 reporting ended · disclosed 2020-06-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,611,215 |
Last balance in matching sequence
After 2020-06-16 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2020-06-16 · Conversion · Acquired 961,215 · Balance 961,215 F1: On June 16, 2020, the Series B Preferred Stock automatically converted into Common Stock on approximately a 1.5546-for-one basis (when rounded to the nearest ten-thousandth) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The securities are owned directly by clients of Casdin Capital, LLC and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC as investment adviser to such clients and (ii) Eli Casdin as managing member of Casdin Capital, LLC. Row 2 · 2020-06-16 · Purchase · Acquired 650,000 · Balance 1,611,215 F3: The securities are owned directly by clients of Casdin Capital, LLC and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC as investment adviser to such clients and (ii) Eli Casdin as managing member of Casdin Capital, LLC. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2020-06-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-06-16 · Conversion · Disposed 1,093,410 · Balance 0 F1: On June 16, 2020, the Series B Preferred Stock automatically converted into Common Stock on approximately a 1.5546-for-one basis (when rounded to the nearest ten-thousandth) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The securities are owned directly by clients of Casdin Capital, LLC and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC as investment adviser to such clients and (ii) Eli Casdin as managing member of Casdin Capital, LLC. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2020-06-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-06-16 · Conversion · Disposed 455,500 · Balance 0 F2: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The securities are owned directly by clients of Casdin Capital, LLC and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC as investment adviser to such clients and (ii) Eli Casdin as managing member of Casdin Capital, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 16, 2020, the Series B Preferred Stock automatically converted into Common Stock on approximately a 1.5546-for-one basis (when rounded to the nearest ten-thousandth) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F3: The securities are owned directly by clients of Casdin Capital, LLC and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC as investment adviser to such clients and (ii) Eli Casdin as managing member of Casdin Capital, LLC.
MAXCYTE, INC.
Report date October 03, 2022 · Filed October 05, 2022
Jointly reported with Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC, Casdin Eli
Section 16 reporting ended · disclosed 2022-10-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | Direct | 10,000,000 |
Reported balance
After 2022-10-03 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-10-03 · Sale · Disposed 735,786 · Balance 10,000,000 F1: (1) The securities are owned directly by Casdin Partners Master Fund, LP (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: (1) The securities are owned directly by Casdin Partners Master Fund, LP (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
Tenaya Therapeutics, Inc.
Report date November 17, 2022 · Filed November 26, 2022
Jointly reported with Casdin Eli
Section 16 reporting ended · disclosed 2022-11-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 6,078,860 |
Reported balance
After 2022-11-17 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-11-17 · Purchase · Acquired 2,492,042 · Balance 6,078,860 F1: The securities are owned directly by clients of Casdin Capital, LLC ("Casdin Capital") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to such clients and (ii) Eli Casdin, the managing member of Casdin Capital. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee footnote | 1,354,111 |
Reported balance
After 2022-11-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-17 · Purchase · Acquired 1,354,111 · Balance 1,354,111 F2: Each Warrant will be exercisable on or after the date of issuance until the date the Warrant is exercised in full. Each Warrant will be exercisable, in the holder's discretion, by (i) payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise or (ii) a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to a pre-set formula. F1: The securities are owned directly by clients of Casdin Capital, LLC ("Casdin Capital") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to such clients and (ii) Eli Casdin, the managing member of Casdin Capital. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities are owned directly by clients of Casdin Capital, LLC ("Casdin Capital") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to such clients and (ii) Eli Casdin, the managing member of Casdin Capital.
F2: Each Warrant will be exercisable on or after the date of issuance until the date the Warrant is exercised in full. Each Warrant will be exercisable, in the holder's discretion, by (i) payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise or (ii) a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to a pre-set formula.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 8, 2026 21:25 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | PurchaseClass A Common Stock, par value $0.0001 per share | 50,000 | $52.86 | $2,642,830.00 |
DisclosureSEC source: 0000919574-26-003907 · ownership.xml · nonDerivative · entry 2 Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,707,164 F1 · ownership.nature: The securities are owned directly by the Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 21:25 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | PurchaseClass A Common Stock, par value $0.0001 per share | 150,000 | $56.44 | $8,466,735.00 |
DisclosureSEC source: 0000919574-26-003907 · ownership.xml · nonDerivative · entry 1 Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,657,164 F1 · ownership.nature: The securities are owned directly by the Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 21, 2026 Filed May 21, 2026 23:10 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock, par value $0.001 per share | 650,000 | $23.70 | $15,405,000.00 |
DisclosureSEC source: 0000919574-26-003646 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner Casdin Capital, LLC · CIK 0001534261 · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · 10% owner Casdin Eli · CIK 0001534264 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 4,757,165 F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin Capital"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Read SEC document |
| May 20, 2026 Filed May 20, 2026 23:45 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | PurchaseClass A Common Stock, par value $0.0001 per share | 140,000 | $43.81 | $6,132,854.00 |
DisclosureSEC source: 0000919574-26-003627 · ownership.xml · nonDerivative · entry 3 Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,507,164 F4 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $43.6287 to $44.3384. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by the Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 20, 2026 Filed May 21, 2026 23:10 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock, par value $0.001 per share | 250,000 | $23.70 | $5,925,000.00 |
DisclosureSEC source: 0000919574-26-003646 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner Casdin Capital, LLC · CIK 0001534261 · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · 10% owner Casdin Eli · CIK 0001534264 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,407,165 F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin Capital"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Read SEC document |
| May 19, 2026 Filed May 20, 2026 23:45 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | PurchaseClass A Common Stock, par value $0.0001 per share | 185,000 | $42.60 | $7,880,334.00 |
DisclosureSEC source: 0000919574-26-003627 · ownership.xml · nonDerivative · entry 2 Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,367,164 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $42.1118 to $42.6898. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by the Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 19, 2026 Filed May 21, 2026 23:10 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock, par value $0.001 per share | 300,000 | $22.65 | $6,795,000.00 |
DisclosureSEC source: 0000919574-26-003646 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner Casdin Capital, LLC · CIK 0001534261 · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · 10% owner Casdin Eli · CIK 0001534264 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,657,165 F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin Capital"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Read SEC document |
| May 18, 2026 Filed May 20, 2026 23:45 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | PurchaseClass A Common Stock, par value $0.0001 per share | 175,000 | $42.55 | $7,446,547.50 |
DisclosureSEC source: 0000919574-26-003627 · ownership.xml · nonDerivative · entry 1 Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,182,164 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $42.4573 to $42.9153. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by the Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 11, 2026 Filed May 12, 2026 00:43 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | PurchaseCash Settled Swap · Derivative | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000919574-26-002845 · ownership.xml · derivative · entry 3 Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 850,000 Underlying: Class A Common Stock · 50,000 shares Expires not disclosed F4 · derivative.exercise_price: The Master Fund has entered into certain cash-settled swap agreements (the "Swap Agreements"), which represent economic exposure to an aggregate of 50,000 notional shares of the Issuer's Class A Common Stock, at a price of $39.6602 per share. The Swap Agreements provide the Master Fund with economic results that are comparable to the economic results of ownership but do not provide it with the power to vote or direct the voting or dispose of or direct the disposition of the securities that are referenced by the Swap Agreements. F4 · price: The Master Fund has entered into certain cash-settled swap agreements (the "Swap Agreements"), which represent economic exposure to an aggregate of 50,000 notional shares of the Issuer's Class A Common Stock, at a price of $39.6602 per share. The Swap Agreements provide the Master Fund with economic results that are comparable to the economic results of ownership but do not provide it with the power to vote or direct the voting or dispose of or direct the disposition of the securities that are referenced by the Swap Agreements. F4 · derivative.exercise_date: The Master Fund has entered into certain cash-settled swap agreements (the "Swap Agreements"), which represent economic exposure to an aggregate of 50,000 notional shares of the Issuer's Class A Common Stock, at a price of $39.6602 per share. The Swap Agreements provide the Master Fund with economic results that are comparable to the economic results of ownership but do not provide it with the power to vote or direct the voting or dispose of or direct the disposition of the securities that are referenced by the Swap Agreements. F4 · derivative.expiration_date: The Master Fund has entered into certain cash-settled swap agreements (the "Swap Agreements"), which represent economic exposure to an aggregate of 50,000 notional shares of the Issuer's Class A Common Stock, at a price of $39.6602 per share. The Swap Agreements provide the Master Fund with economic results that are comparable to the economic results of ownership but do not provide it with the power to vote or direct the voting or dispose of or direct the disposition of the securities that are referenced by the Swap Agreements. F2 · ownership.nature: The Swap Agreements are owned directly by the Master Fund and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 08, 2026 Filed May 12, 2026 00:43 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | PurchaseCash Settled Swap · Derivative | 300,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000919574-26-002845 · ownership.xml · derivative · entry 2 Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 800,000 Underlying: Class A Common Stock · 300,000 shares Expires not disclosed F3 · derivative.exercise_price: The Master Fund has entered into certain cash-settled swap agreements (the "Swap Agreements"), which represent economic exposure to an aggregate of 300,000 notional shares of the Issuer's Class A Common Stock, at a price of $41.0261 per share. The Swap Agreements provide the Master Fund with economic results that are comparable to the economic results of ownership but do not provide it with the power to vote or direct the voting or dispose of or direct the disposition of the securities that are referenced by the Swap Agreements. F3 · price: The Master Fund has entered into certain cash-settled swap agreements (the "Swap Agreements"), which represent economic exposure to an aggregate of 300,000 notional shares of the Issuer's Class A Common Stock, at a price of $41.0261 per share. The Swap Agreements provide the Master Fund with economic results that are comparable to the economic results of ownership but do not provide it with the power to vote or direct the voting or dispose of or direct the disposition of the securities that are referenced by the Swap Agreements. F3 · derivative.exercise_date: The Master Fund has entered into certain cash-settled swap agreements (the "Swap Agreements"), which represent economic exposure to an aggregate of 300,000 notional shares of the Issuer's Class A Common Stock, at a price of $41.0261 per share. The Swap Agreements provide the Master Fund with economic results that are comparable to the economic results of ownership but do not provide it with the power to vote or direct the voting or dispose of or direct the disposition of the securities that are referenced by the Swap Agreements. F3 · derivative.expiration_date: The Master Fund has entered into certain cash-settled swap agreements (the "Swap Agreements"), which represent economic exposure to an aggregate of 300,000 notional shares of the Issuer's Class A Common Stock, at a price of $41.0261 per share. The Swap Agreements provide the Master Fund with economic results that are comparable to the economic results of ownership but do not provide it with the power to vote or direct the voting or dispose of or direct the disposition of the securities that are referenced by the Swap Agreements. F2 · ownership.nature: The Swap Agreements are owned directly by the Master Fund and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 07, 2026 Filed May 12, 2026 00:43 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | PurchaseCash Settled Swap · Derivative | 500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000919574-26-002845 · ownership.xml · derivative · entry 1 Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 500,000 Underlying: Class A Common Stock · 500,000 shares Expires not disclosed F1 · derivative.exercise_price: Casdin Partners Master Fund, L.P. (the "Master Fund") has entered into certain cash-settled swap agreements (the "Swap Agreements"), which represent economic exposure to an aggregate of 500,000 notional shares of the Issuer's Class A Common Stock, at a price of $38.1543 per share. The Swap Agreements provide the Master Fund with economic results that are comparable to the economic results of ownership but do not provide it with the power to vote or direct the voting or dispose of or direct the disposition of the securities that are referenced by the Swap Agreements. F1 · price: Casdin Partners Master Fund, L.P. (the "Master Fund") has entered into certain cash-settled swap agreements (the "Swap Agreements"), which represent economic exposure to an aggregate of 500,000 notional shares of the Issuer's Class A Common Stock, at a price of $38.1543 per share. The Swap Agreements provide the Master Fund with economic results that are comparable to the economic results of ownership but do not provide it with the power to vote or direct the voting or dispose of or direct the disposition of the securities that are referenced by the Swap Agreements. F1 · derivative.exercise_date: Casdin Partners Master Fund, L.P. (the "Master Fund") has entered into certain cash-settled swap agreements (the "Swap Agreements"), which represent economic exposure to an aggregate of 500,000 notional shares of the Issuer's Class A Common Stock, at a price of $38.1543 per share. The Swap Agreements provide the Master Fund with economic results that are comparable to the economic results of ownership but do not provide it with the power to vote or direct the voting or dispose of or direct the disposition of the securities that are referenced by the Swap Agreements. F1 · derivative.expiration_date: Casdin Partners Master Fund, L.P. (the "Master Fund") has entered into certain cash-settled swap agreements (the "Swap Agreements"), which represent economic exposure to an aggregate of 500,000 notional shares of the Issuer's Class A Common Stock, at a price of $38.1543 per share. The Swap Agreements provide the Master Fund with economic results that are comparable to the economic results of ownership but do not provide it with the power to vote or direct the voting or dispose of or direct the disposition of the securities that are referenced by the Swap Agreements. F2 · ownership.nature: The Swap Agreements are owned directly by the Master Fund and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 01:59 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 150,000 | $1.45 | $217,020.00 |
DisclosureSEC source: 0000919574-25-007243 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 72,100,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4331 to $1.4588. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 01:59 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 75,000 | $1.44 | $108,037.50 |
DisclosureSEC source: 0000919574-25-007243 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 71,950,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4403 to $1.4406. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 01:59 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 125,000 | $1.42 | $177,512.50 |
DisclosureSEC source: 0000919574-25-007243 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 71,875,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4050 to $1.4351. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 21:58 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 7,550,000 | $1.30 | $9,838,405.00 |
DisclosureSEC source: 0000919574-25-007187 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 71,750,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.30 to $1.3843. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 21:58 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 150,000 | $1.43 | $214,875.00 |
DisclosureSEC source: 0000919574-25-007187 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 64,200,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4290 to $1.4396. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| November 20, 2025 Filed Nov 21, 2025 00:45 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 450,000 | $1.30 | $586,260.00 |
DisclosureSEC source: 0000919574-25-007124 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 64,050,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2788 to $1.3500 . The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 00:45 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 350,000 | $1.28 | $448,910.00 |
DisclosureSEC source: 0000919574-25-007124 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 63,600,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2758 to $1.2870. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| November 18, 2025 Filed Nov 21, 2025 00:45 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 275,000 | $1.23 | $339,405.00 |
DisclosureSEC source: 0000919574-25-007124 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 63,250,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2247 to $1.2421. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| November 17, 2025 Filed Nov 17, 2025 23:58 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 225,000 | $1.22 | $275,580.00 |
DisclosureSEC source: 0000919574-25-007087 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 62,975,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2175 to $1.2299. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| November 14, 2025 Filed Nov 17, 2025 23:58 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 250,000 | $1.24 | $309,800.00 |
DisclosureSEC source: 0000919574-25-007087 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 62,750,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2364 to $1.2434. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 23:58 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 450,000 | $1.20 | $541,395.00 |
DisclosureSEC source: 0000919574-25-007087 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 62,500,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.1978 to $1.2098. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 00:46 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 375,000 | $1.19 | $445,837.50 |
DisclosureSEC source: 0000919574-25-006597 · ownership.xml · nonDerivative · entry 4 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 62,050,000 F4 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.1865 to $1.1913. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 00:46 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 300,000 | $1.20 | $358,800.00 |
DisclosureSEC source: 0000919574-25-006597 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 61,675,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.1881 to $1.2053. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| November 10, 2025 Filed Nov 13, 2025 00:46 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 275,000 | $1.17 | $321,915.00 |
DisclosureSEC source: 0000919574-25-006597 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 61,375,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.1688 to $1.1732. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| November 07, 2025 Filed Nov 13, 2025 00:46 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 225,000 | $1.12 | $252,765.00 |
DisclosureSEC source: 0000919574-25-006597 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 61,100,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.1153 to $1.1321. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 23:55 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock, par value $0.001 per share | 750,000 | $28.55 | $21,410,325.00 |
DisclosureSEC source: 0000919574-25-006180 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner Casdin Capital, LLC · CIK 0001534261 · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · 10% owner Casdin Eli · CIK 0001534264 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Footonote Disclosed balance after: 5,957,165 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $28.50 to $28.8354. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin Capital"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Read SEC document |
| September 09, 2025 Filed Sep 12, 2025 01:03 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 100,000 | $1.29 | $128,920.00 |
DisclosureSEC source: 0000919574-25-005636 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 60,875,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2889 to $1.2895. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| September 04, 2025 Filed Sep 5, 2025 23:08 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 250,000 | $1.28 | $319,350.00 |
DisclosureSEC source: 0000919574-25-005603 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 60,775,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2621 to $1.2930. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 23:08 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 250,000 | $1.27 | $316,400.00 |
DisclosureSEC source: 0000919574-25-005603 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 60,525,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2414 to $1.2765. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 26, 2025 Filed Aug 27, 2025 00:46 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 125,000 | $1.26 | $157,937.50 |
DisclosureSEC source: 0000919574-25-005152 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 60,275,000 F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 00:46 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 200,000 | $1.24 | $248,180.00 |
DisclosureSEC source: 0000919574-25-005152 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 60,150,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2311 to $1.2475. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 22, 2025 Filed Aug 22, 2025 22:55 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 500,000 | $120.90 | $60,451,950.00 |
DisclosureSEC source: 0000919574-25-005084 · ownership.xml · nonDerivative · entry 1 Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,007,164 F1 · ownership.nature: The securities are owned directly by the Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 22, 2025 Filed Aug 27, 2025 00:46 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 200,000 | $1.26 | $252,680.00 |
DisclosureSEC source: 0000919574-25-005152 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 59,950,000 F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 15, 2025 Filed Aug 16, 2025 01:18 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 150,000 | $1.22 | $183,210.00 |
DisclosureSEC source: 0000919574-25-004979 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 59,750,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2179 to $1.2232. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 15, 2025 Filed Aug 22, 2025 01:10 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock, par value $0.001 per share | 500,000 | $24.40 | $12,200,000.00 |
DisclosureSEC source: 0000919574-25-005051 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner Casdin Capital, LLC · CIK 0001534261 · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · 10% owner Casdin Eli · CIK 0001534264 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 6,707,165 F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin Capital"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Read SEC document |
| August 14, 2025 Filed Aug 16, 2025 01:18 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 133,220 | $1.21 | $161,542.57 |
DisclosureSEC source: 0000919574-25-004979 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 59,600,000 F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 13, 2025 Filed Aug 16, 2025 01:18 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 75,000 | $1.31 | $98,280.00 |
DisclosureSEC source: 0000919574-25-004979 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 59,466,780 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.3075 to $1.3118. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 22:43 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock, par value $0.001 per share | 500,000 | $22.60 | $11,300,000.00 |
DisclosureSEC source: 0000919574-25-004702 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner Casdin Capital, LLC · CIK 0001534261 · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · 10% owner Casdin Eli · CIK 0001534264 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 7,207,165 F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin Capital"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 00:27 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock, par value $0.001 per share | 1,000,000 | $23.80 | $23,800,000.00 |
DisclosureSEC source: 0000919574-25-003572 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner Casdin Capital, LLC · CIK 0001534261 · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · 10% owner Casdin Eli · CIK 0001534264 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 7,707,165 F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin Capital"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Read SEC document |
| May 13, 2025 Filed May 15, 2025 16:51 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | Disposition to issuerStock Options (Right to buy) · Derivative | 33,400 | Not disclosed Strike: $4.54 | Not disclosed |
DisclosureSEC source: 0000919574-25-003264 · ownership.xml · derivative · entry 4 Casdin Capital, LLC · CIK 0001534261 · Director Casdin Eli · CIK 0001534264 · Director Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 per share · 33,400 shares Expires not disclosed F5 · shares: Each option to purchase Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company Option immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. F5 · price: Each option to purchase Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company Option immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. F5 · derivative.exercise_date: Each option to purchase Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company Option immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. F5 · derivative.expiration_date: Each option to purchase Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company Option immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. F3 · ownership.direct: The securities were owned directly by Eli Casdin. Read SEC document |
| May 13, 2025 Filed May 15, 2025 16:51 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | Disposition to issuerStock Options (Right to buy) · Derivative | 12,050 | Not disclosed Strike: $3.93 | Not disclosed |
DisclosureSEC source: 0000919574-25-003264 · ownership.xml · derivative · entry 3 Casdin Capital, LLC · CIK 0001534261 · Director Casdin Eli · CIK 0001534264 · Director Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 per share · 12,050 shares Expires not disclosed F5 · shares: Each option to purchase Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company Option immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. F5 · price: Each option to purchase Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company Option immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. F5 · derivative.exercise_date: Each option to purchase Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company Option immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. F5 · derivative.expiration_date: Each option to purchase Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company Option immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. F3 · ownership.direct: The securities were owned directly by Eli Casdin. Read SEC document |
| May 13, 2025 Filed May 15, 2025 16:51 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | OtherCommon Stock, par value $0.0001 per share | 2,000,000 | $5.00 | $10,000,000.00 |
DisclosureSEC source: 0000919574-25-003264 · ownership.xml · nonDerivative · entry 2 Casdin Capital, LLC · CIK 0001534261 · Director Casdin Eli · CIK 0001534264 · Director Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: Represents securities that were tendered in connection with the Agreement and Plan of Merger (the "Merger Agreement"), dated March 10, 2025, by and among 2seventy bio, Inc. (the "Company"), Daybreak Merger Sub Inc. ("Merger Sub") and Bristol-Myers Squibb Company ("Parent"). Following completion of a cash tender offer by Merger Sub to acquire all of the issued and outstanding shares of the Company's common stock, par value $0.0001 per share (the "Company Common Stock") for $5.00 per share (the "Merger Consideration"), Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a whole owned subsidiary of Parent (the "Merger"). F2 · kind: cont'd from footnote (1): Each restricted stock unit in respect of Company Common Stock ("Company RSU Award"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Additionally, effective as of the Effective Time and as a result of the Merger, Eli Casdin ceased to be a member of the Company's board of directors. F1 · price: Represents securities that were tendered in connection with the Agreement and Plan of Merger (the "Merger Agreement"), dated March 10, 2025, by and among 2seventy bio, Inc. (the "Company"), Daybreak Merger Sub Inc. ("Merger Sub") and Bristol-Myers Squibb Company ("Parent"). Following completion of a cash tender offer by Merger Sub to acquire all of the issued and outstanding shares of the Company's common stock, par value $0.0001 per share (the "Company Common Stock") for $5.00 per share (the "Merger Consideration"), Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a whole owned subsidiary of Parent (the "Merger"). F2 · price: cont'd from footnote (1): Each restricted stock unit in respect of Company Common Stock ("Company RSU Award"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Additionally, effective as of the Effective Time and as a result of the Merger, Eli Casdin ceased to be a member of the Company's board of directors. F4 · ownership.nature: The securities were owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to have been indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 13, 2025 Filed May 15, 2025 16:51 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | OtherCommon Stock, par value $0.0001 per share | 22,625 | $5.00 | $113,125.00 |
DisclosureSEC source: 0000919574-25-003264 · ownership.xml · nonDerivative · entry 1 Casdin Capital, LLC · CIK 0001534261 · Director Casdin Eli · CIK 0001534264 · Director Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Represents securities that were tendered in connection with the Agreement and Plan of Merger (the "Merger Agreement"), dated March 10, 2025, by and among 2seventy bio, Inc. (the "Company"), Daybreak Merger Sub Inc. ("Merger Sub") and Bristol-Myers Squibb Company ("Parent"). Following completion of a cash tender offer by Merger Sub to acquire all of the issued and outstanding shares of the Company's common stock, par value $0.0001 per share (the "Company Common Stock") for $5.00 per share (the "Merger Consideration"), Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a whole owned subsidiary of Parent (the "Merger"). F2 · kind: cont'd from footnote (1): Each restricted stock unit in respect of Company Common Stock ("Company RSU Award"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Additionally, effective as of the Effective Time and as a result of the Merger, Eli Casdin ceased to be a member of the Company's board of directors. F1 · price: Represents securities that were tendered in connection with the Agreement and Plan of Merger (the "Merger Agreement"), dated March 10, 2025, by and among 2seventy bio, Inc. (the "Company"), Daybreak Merger Sub Inc. ("Merger Sub") and Bristol-Myers Squibb Company ("Parent"). Following completion of a cash tender offer by Merger Sub to acquire all of the issued and outstanding shares of the Company's common stock, par value $0.0001 per share (the "Company Common Stock") for $5.00 per share (the "Merger Consideration"), Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a whole owned subsidiary of Parent (the "Merger"). F2 · price: cont'd from footnote (1): Each restricted stock unit in respect of Company Common Stock ("Company RSU Award"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Additionally, effective as of the Effective Time and as a result of the Merger, Eli Casdin ceased to be a member of the Company's board of directors. F3 · ownership.direct: The securities were owned directly by Eli Casdin. Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 21:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | OtherCommon Stock, par value $.001 per share | 27,994 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000919574-25-002362 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner Casdin Capital, LLC · CIK 0001534261 · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · 10% owner Casdin Eli · CIK 0001534264 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 8,735,159 F1 · kind: Received in exchange for shares of common stock of PanThera CryoSolutions, Inc. ("PanThera") pursuant to the acquisition of PanThera by Biolife Solutions Inc (the "Company"). Per the terms of the acquisition, the Company purchased 90% of PanTHERA common shares it did not own for $9.3 million in cash and 241,355 shares of the Company's Common Stock, par value $.001 per share. The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. F1 · price: Received in exchange for shares of common stock of PanThera CryoSolutions, Inc. ("PanThera") pursuant to the acquisition of PanThera by Biolife Solutions Inc (the "Company"). Per the terms of the acquisition, the Company purchased 90% of PanTHERA common shares it did not own for $9.3 million in cash and 241,355 shares of the Company's Common Stock, par value $.001 per share. The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. F1 · ownership.nature: Received in exchange for shares of common stock of PanThera CryoSolutions, Inc. ("PanThera") pursuant to the acquisition of PanThera by Biolife Solutions Inc (the "Company"). Per the terms of the acquisition, the Company purchased 90% of PanTHERA common shares it did not own for $9.3 million in cash and 241,355 shares of the Company's Common Stock, par value $.001 per share. The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 01:19 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 58,215 | $1.07 | $61,998.98 |
DisclosureSEC source: 0000919574-25-001777 · ownership.xml · nonDerivative · entry 4 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,806,470 F4 · shares: Represents Restricted Stock Units ("RSUs") that vest as to 25% on the last day of the last month of each fiscal quarter of 2025, subject to the Reporting Person's continued service through the applicable vesting date. F5 · price: The RSUs were issued to the Reporting Person, who elected to take RSUs in lieu of $62,000 in cash compensation for services as a board member. F6 · balance_after: Includes RSUs. F7 · ownership.direct: The securities are owned directly by Eli Casdin. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 01:19 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | OtherCommon Stock | 545,000 | $1.07 | $580,425.00 |
DisclosureSEC source: 0000919574-25-001777 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F2 · kind: Represents a cross-trade, pursuant to which Casdin Amplify Fund, LP ("Amplify") transferred 545,000 shares of Common Stock to the Master Fund. F3 · ownership.nature: The securities were owned directly by Amplify and were deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Amplify, (ii) the GP, the general partner of Amplify, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 01:19 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | OtherCommon Stock | 545,000 | $1.07 | $580,425.00 |
DisclosureSEC source: 0000919574-25-001777 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 59,391,780 F2 · kind: Represents a cross-trade, pursuant to which Casdin Amplify Fund, LP ("Amplify") transferred 545,000 shares of Common Stock to the Master Fund. F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 01:19 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 4,820,959 | $1.07 | $5,134,321.34 |
DisclosureSEC source: 0000919574-25-001777 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 58,846,780 F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 27, 2024 Filed Aug 30, 2024 00:30 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 250,000 | $2.19 | $546,750.00 |
DisclosureSEC source: 0000919574-24-005134 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 54,025,821 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.1746 to $2.1953. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.